2. Search Result
Search Result
Results for "

biliary diseases

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Fluorescent Dyes

2

Inhibitory Antibodies

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-133707
    β-Muricholic acid
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .
    β-Muricholic acid
  • HY-126995
    Glycohyodeoxycholic acid

    		Endogenous Metabolite Metabolic Disease
    Glycohyodeoxycholic acid is a glycine-conjugated bile acid and also a metabolite of Hyodeoxycholic acid (HY-N0169). The serum level of Glycohyodeoxycholic acid is negatively correlated with the severity of non-alcoholic fatty liver disease. Glycohyodeoxycholic acid can be used in research related to non-alcoholic fatty liver disease .
    Glycohyodeoxycholic acid
  • HY-114360
    Taurohyodeoxycholic acid
    2 Publications Verification

    		 Endogenous Metabolite COX Interleukin Related Glutathione Peroxidase TNF Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula .
    Taurohyodeoxycholic acid
  • HY-16747
    Maralixibat chloride

    SHP625 chloride; LUM001 chloride; Lopixibat chloride

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia .
    Maralixibat chloride
  • HY-P99404
    Quetmolimab

    E6011

    		 CXCR Inflammation/Immunology Cancer
    Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .
    Quetmolimab
  • HY-N6987
    Licraside

    		FXR Factor Xa Cardiovascular Disease Inflammation/Immunology
    Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC50 of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases .
    Licraside
  • HY-E70413
    Amino acid arylamidase, hog kidney

    		Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Amino acid arylamidase, hog kidney is a metalloprotease that can hydrolyze proteins or peptides containing free α-amino or α-imino groups, playing a crucial role in amino acid metabolism and protein digestion. Its hydrolytic activity can be blocked by acetylation of the N-terminus. Amino acid arylamidase, hog kidney can be used in research on hepatic diseases, biliary diseases, and heart failure .
    Amino acid arylamidase, hog kidney
  • HY-P991554
    FFP-104

    		TNF Receptor Inflammation/Immunology
    FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
    FFP-104
  • HY-106537
    W 3699

    Probilin; Secrebil; Piprozolin

    		 Others Metabolic Disease
    W 3699 (Probilin; Secrebil; Piprozolin) is a choleretic agent that can be used in the study of biliary diseases .
    W 3699
  • HY-105526
    Trimethylcolchicinic acid

    Desacetylcolchiceine; N-Deacetylcolchiceine

    		 Microtubule/Tubulin Metabolic Disease Cancer
    Trimethylcolchicinic acid (Desacetylcolchiceine; N-Deacetylcolchiceine) is a colchicine analogue. Trimethylcolchicinic acid promotes the production of chondroitin sulfate in L cells and inhibits the production of dermatan sulfate. Trimethylcolchicinic acid reduces liver fibrosis and cholestasis induced by long-term biliary obstruction in rats. Trimethylcolchicinic acid has potential for use in research on diseases such as liver fibrosis, gout, and cancer .
    Trimethylcolchicinic acid
  • HY-113238F
    FITC-Lithocholic acid 3-sulfate

    FITC-Sulfolithocholic acid

    		 Fluorescent Dye Others
    FITC-Lithocholic acid 3-sulfate (FITC-Sulfolithocholic acid) is a FITC-labeled Lithocholic acid 3-sulfate, which is a sulfated biliary metabolite. Lithocholic acid 3-sulfate selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate can be used for the research of pathogenesis of cholestatic liver diseases .
    FITC-Lithocholic acid 3-sulfate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: